Department of Pediatrics

Clinical Interests

Dr. Shenoy's research interests are focused on stem cell transplants for non-malignant disorders, reduced intensity transplants, and the immunologic mechanisms of graft rejection, graft versus host disease (GVHD), and immune reconstitution following stem cell transplantation (SCT). These efforts are directed at making SCT safer and better tolerated by reducing associated toxicities, especially as it relates to non-malignant disorders such as hemoglobinopathy. She is the Prinicipal Investigator of national trials of unrelated donor transplantation for severe sickle cell disease termed the SCURT Trial (Bone Marrow Transplant Clinical Trials Network 0601, NHLBI) and thalassemia termed the URTH Trial (Thalassemia Clinical Research Network, NHLBI). Other clinical trials for additional non-malignant disorders such as bone marrow failure syndromes using alternative and minimally mismatched donors are also underway.

Education

• MBBS, Kasturba Medical College, 1981
• MD, Kasturba Medical College, 1985
• MD, Louisiana State University Medical Center, 1991
• MD, Washington University in St. Louis, 1996

Training

• Residency in Pediatrics, Kasturba Medical College, 1982 - 1985
• Residency in Pediatrics, Louisiana State University Medical Center, 1989 - 1991
• Fellowship in Pediatric Hematology Oncology, Washington University in St. Louis, 1992 - 1996

Licensure and Board Certification

• MO, MD
• Pediatric Hematology Oncology

Honors and Awards

• American Society of Histocompatibility and Immunogenetics Scholar Award, 2001 - 2001
• Fred Saunders Lecture Award, CBMTG, 2012 - 2012
• Teresa J Vietti MD Scholar in Pediatrics, Washington University School of Medicine in St. Louis, 2014 - Pres

Recent Publications view all (81)

Publication Co-Authors

Todd Druley, M.D., Ph.D.

Stuart C. Sweet, M.D., Ph.D.

Jeffrey J. Bednarski, M.D., Ph.D.

Lori R. Holtz, M.D., M.S.P.H.

S. Paul Hmiel, M.D., Ph.D.

Thomas Ferkol, M.D.

Sima Bhatt

Monica Hulbert, M.D.

Charles Canter, M.D.

Andrew Cluster

Allison King, M.D., M.P.H., Ph.D.

David B. Wilson, M.D., Ph.D.

Rakesh Rao, M.D.

Alok Kothari, M.D.

Yumirle Turmelle, M.D., M.S.P.H.

Robert J. Hayashi, M.D.

Washington University has a long tradition of collaboration amongst colleagues.The faculty above have co-authored publications with Shalini Shenoy, M.D.

1. Davies SM, Iannone R, Alonzo TA, Wang YC, Gerbing R, Soni S, Kolb EA, Meshinchi S, Orchard PJ, Burns LJ, Shenoy S, Leung W.. A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study Biology of Blood and Marrow Transplantation. 2019;pii: S1083-8791(19):31652-0. doi:10.1016/j.bbmt.2019.12.723  
2. Farrell AT, Panepinto J, Desai AA, Kassim AA, Lebensburger J, Walters MC, Bauer DE, Blaylark RM, DiMichele DM, Gladwin MT, Green NS, Hassell K, Kato GJ, Klings ES, Kohn DB, Krishnamurti L, Little J, Makani J, Malik P, McGann PT, Minniti C, Morris CR, Odame I, Oneal PA, Setse R, Sharma P, Shenoy S.. End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings Blood Advances. 2019;10;3(23):4002-4020. doi:10.1182/bloodadvances.2019000883  PMID:31809537 
3. Cairo MS, Talano JA, Moore TB, Shi Q, Weinberg RS, Grossman B, Shenoy S. Familial Haploidentical Stem Cell Transplant in Children and Adolescents With High-Risk Sickle Cell Disease: A Phase 2 Clinical Trial JAMA Pediatrics. 2019. doi:doi: 10.1001/jamapediatrics.2019.4715  PMID:31816036 
4. Stenger EO, Shenoy S, Krishnamurti L.. How I treat sickle cell disease with hematopoietic cell transplantation. Blood. 2019;134(25):2249-2260. doi:10.1182/blood.2019000821  PMID:31697818 
5. Marsh RA, Leiding JW, Logan BR, Griffith LM, Arnold DE, Haddad E, Falcone EL, Yin Z, Patel K, Arbuckle E, Bleesing JJ, Sullivan KE, Heimall J, Burroughs LM, Skoda-Smith S, Chandrakasan S, Yu LC, Oshrine BR, Cuvelier GDE, Thakar MS, Chen K, Teira P, Shenoy S, Phelan R, Forbes LR, Chellapandian D, Dávila Saldaña BJ, Shah AJ, Weinacht KG, Joshi A, Boulad F, Quigg TC, Dvorak CC, Grossman D, Torgerson T, Graham P, Prasad V, Knutsen A, Chong H, Miller H, de la Morena MT, DeSantes K, Cowan MJ, Notarangelo LD, Kohn DB, Stenger E, Pai SY, Routes JM, Puck JM, Kapoor N, Pulsipher MA, Malech HL, Parikh S, Kang EM; submitted on behalf of the Primary Immune Deficiency Treatment Consortium.. Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. J Clin Immunol. 2019;39(7):653-67.. PMID:31376032 
6. Li C, Mathews V, Kim S, George B, Hebert K, Jiang H, Li C, Zhu Y, Keesler DA, Boelens JJ, Dvorak CC, Agarwal R, Auletta JJ, Goyal RK, Hanna R, Kasow K, Shenoy S, Smith AR, Walters MC, Eapen M.. Related and unrelated donor transplantation for β-thalassemia major: results of an international survey. Blood Adv. 2019;3(17):2562-70.. PMID:31471325  
7. Eapen M, Brazauskas R, Walters MC, Bernaudin F, Bo-Subait K, Fitzhugh CD, Hankins JS, Kanter J, Meerpohl JJ, Bolaños-Meade J, Panepinto JA, Rondelli D, Shenoy S, Williamson J, Woolford TL, Gluckman E, Wagner JE, Tisdale JF.. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. Lancet Haematol. 2019;E Pub S2352-3026(19)30154-1. PMID:31495699 
8. Hall E, Shenoy S. Hematopoietic Stem Cell Transplantation: A Neonatal Perspective. Neoreviews. 2019;20(6):e336-e345. PMID:31261097  
9. Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Ball ED, Bolwell BJ, Bunin NJ, Cheerva A, Delgado DC, Dvorak CC, Gillio AP, Hahn TE, Hale GA, Haight AE, Hayes-Lattin BM, Kasow KA, Linenberger M, Magalhaes-Silverman M, Mori S, Prasad VK, Quigg TC, Sahdev I, Schriber JR, Shenoy S, Tse WT, Yanik GA, Navarro WH, Horowitz MM, Confer DL, Shaw BE, Switzer GE.. Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results. Biol Blood Marrow Transplant. 2019;25(5):955-964. PMID:30605731 
10. Michael A Pulsipher, Brent R Logan, Pintip Chitphakdithai, Deidre M Kiefer, Marcie L Riches, J Douglas Rizzo, Paolo Anderlini, Susan F Leitman, James W Varni, Hati Kobusingye, RaeAnne M Besser, John P Miller, Rebecca J Drexler, Aly Abdel-Mageed, Ibrahim A Ahmed, Luke P Akard, Andrew S Artz, Edward D Ball, Ruthee-Lu Bayer, Carolyn Bigelow, Brian J Bolwell, E Randolph Broun, Nancy J Bunin, David C Delgado, Katharine Duckworth, Christopher C Dvorak, Theresa E Hahn, Ann E Haight, Parameswaran N Hari, Brandon M Hayes-Lattin, David A Jacobsohn, Ann A Jakubowski, Kimberly A Kasow, Hillard M Lazarus, Jane L Liesveld, Michael Linenberger, Mark R Litzow, Walter Longo, Margarida Magalhaes-Silverman, John M McCarty, Joseph P McGuirk, Shahram Mori, Vinod K Prasad, Scott D Rowley, Witold B Rybka, Indira Sahdev, Jeffrey R Schriber, George B Selby, Paul J Shaughnessy, Shalini Shenoy, Thomas Spitzer, William T Tse, Joseph P Uberti, Madhuri Vusirikala, Edmund K Waller, Daniel J Weisdorf, Gregory A Yanik, Willis H Navarro, Mary M Horowitz, Galen E Switzer, Bronwen E Shaw, Dennis L Confer. Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. Biology of Blood and Marrow Transplantation. 2019;25(4):699-711. doi:https://doi.org/10.1016/j.bbmt.2018.11.004  
11. King AA, McKinstry RC, Wu J, Eapen M, Abel R, Varughese T, Kamani N, Shenoy S. Functional and Radiologic Assessment of the Brain after Reduced-Intensity Unrelated Donor Transplantation for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network Study 0601. Biol Blood Marrow Transplant.. 2019. PMID:30639825 
12. Dvorak CC, Haddad E, Buckley RH, Cowan MJ, Logan B, Griffith LM, Kohn DB, Pai SY, Notarangelo L, Shearer W, Prockop S, Kapoor N, Heimall J, Chaudhury S, Shyr D, Chandra S, Cuvelier G, Moore T, Shenoy S, Goldman F, Smith AR, Sunkersett G, Vander Lugt M, Caywood E, Quigg T, Torgerson T, Chandrakasan S, Craddock J, Dávila Saldaña BJ, Gillio A, Shereck E, Aquino V, DeSantes K, Knutsen A, Thakar M, Yu L, Puck JM. The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018). J Allergy Clin Immunol. 2019;143(1):405-407. PMCID:PMC6322970  PMID:30193840 
13. Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Parameswaran V, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Confer DL, Shaw BE. Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at 1-year compared to unrelated donors. haematol. 2018. doi:10.3324/haematol.2018.200121  
14. Bhatt ST, Bednarski JJ, Berg J, Trinkaus K, Murray L, Hayashi R, Schulz G, Hente M, Grimley M, Chan KW, Kamani N, Jacobsohn D, Nieder M, Hale G, Yu L, Adams R, Dalal J, Pulsipher MA, Haut P, Chaudhury S, Davis J, Jaroscak J, Andreansky M, Willert J, Shenoy S. Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients. Biol Blood Marrow Transplant. 2018. PMID:30321596 
15. Allen, C. E., Marsh, R., Dawson, P., Bollard, C. M., Shenoy, S., Roehrs, P., Hanna, R., Burroughs, L., Kean, L., Talano, J., Schultz, K. R., Pai, S., Baker, K. S., Andolina, J. R., Stenger, E. O., Connelly, J., Ramirez, A., Bryant, C., Eapen, M., & Pulsipher, M. A.. Reduced intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies: BMT CTN 1204 Blood. 2018;132(13):1438-1451. doi:https://doi.org/10.1182/blood-2018-01-828277  
16. Jacobsohn DA, Loken MR, Fei M, Adams A, Brodersen LE, Logan BR, Ahn KW, Shaw BE, Kletzel M, Olszewski M, Khan S, Meshinchi S, Keating A, Harris A, Teira P, Duerst RE, Margossian SP, Martin PL, Petrovic A, Dvorak CC, Nemecek ER, Boyer MW, Chen AR, Davis JH, Shenoy S, Savasan S, Hudspeth MP, Adams RH, Lewis VA, Kheradpour A, Kasow KA, Gillio AP, Haight AE, Bhatia M, Bambach BJ, Haines HL, Quigg TC, Greiner RJ, Talano JM, Delgado DC, Cheerva A, Gowda M, Ahuja S, Ozkaynak M, Mitchell D, Schultz KR, Fry TJ, Loeb DM, Pulsipher MA. Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression 2018;24(10):2040-2046. doi:https://doi.org/10.1016/j.bbmt.2018.06.010  
17. Shenoy S, Gaziev J, Angelucci E, King A, Bhatia M, Smith A, Bresters D, Haight AE, Duncan CN, de la Fuente J, Dietz AC, Baker KS, Pulsipher MA, Walters MC.. Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Hemoglobinopathy: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT.  Biol Blood Marrow Transplant.. 2018;24(7):1313-21.. PMID:29653206 
18. Hulbert ML, Shenoy S. Hematopoietic stem cell transplantation for sickle cell disease: Progress and challenges. Pediatr Blood Cancer. 2018;e27263. PMID:29797658 
19. Schulz GL, Foster RH, Kennedy Lang V, Towerman A, Shenoy S, Lauer BA, Molzon E, Holtmann M. Early Identification of Barriers and Facilitators to Self-Management Behaviors in Pediatric Patients With Sickle Cell Disease to Minimize Hematopoietic Cell Transplantation Complications. J Pediatr Oncol Nurs. 2018;35(3):199-209. doi:10.1177/1043454218762703  PMID:29577801 
20. Qayed M, Wang T, Hemmer MT, Spellman S, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Aljurf M, Ayas M, Bitan M, Cairo M, Choi SW, Dandoy C, Delgado D, Gale RP, Hale G, Frangoul H, Kamble RT, Kharfan-Dabaja M, Lehman L, Levine J, MacMillan M, Marks DI, Nishihori T, Olsson RF, Hematti P, Ringden O, Saad A, Satwani P, Savani BN, Schultz KR, Seo S, Shenoy S, Waller EK, Yu L, Horowitz MM, Horan J.. Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. Biol Blood Marrow Transplant. 2018;24(3):521-528. PMID:29155316  
21. Guilcher GMT, Shah R, Shenoy S. Principles of alemtuzumab immunoablation in hematopoietic cell transplantation for non-malignant diseases in children: A review. Pediatr Transplant. 2018;22(2). doi:10.1111/petr.13142  PMID:29352515 
22. Shenoy S, Walters MC, Ngwube A, Soni S, Jacobsohn D, Chaudhury S, Grimley M, Chan K, Haight A, Kasow KA, Parikh S, Andreansky M, Connelly J, Delgado D, Godder K, Hale G, Nieder M, Pulsipher MA, Trachtenberg F, Neufeld E, Kwiatkowski JL, Thompson AA. Unrelated Donor Transplantation in Children with Thalassemia Using Reduced Intensity Conditioning - the URTH Trial. Biol Blood Marrow Transplant. 2018. PMID:29374585 
23. Wilson DB, Bessler M, Ferkol TW, Shenoy S, Amano N, Ishii T, Shima H, Narumi S. Comment on: Acquired monosomy 7 myelodysplastic syndrome in a child with clinical features of dyskeratosis congenita and IMAGe association. Pediatr Blood Cancer. 2018;65(1). PMID:28834235 
24. Chaudhury S, Ayas M, Rosen C, Ma M, Vigaruddin M, Parikh S, Kharbanda S, Chiang KY, Haight A, Bhatia M, Guilcher G, Thompson A, Shenoy S. A Multicenter Retrospective Analysis Stressing the Importance of Long-Term Follow-Up after Hematopoietic Cell Transplantation for B-Thalassemia. Biol Blood Marrow Transplant. 2017;10:1695-1700. doi:10.1016/j.bbmt.2017.06.004  PMID:28627425 
25. Abraham A, Hsieh M, Eapen M, Fitzhugh C, Carreras J, Kessler D, Guilcher G, Kamani N, Walters MC, Boelens JJ, Tisdale J, Shenoy S, National Institutes of Health., Center for International Blood and Marrow Transplant Research.. Relationship between Mixed Donor-Recipient Chimerism and Disease Recurrence Following Hematopoietic Cell Transplantation for Sickle Cell Disease. Biol Blood Marrow Transplant. 2017. PMID:28882446 
26. Bhandari R, Lindley A, Bhatla D, Babic A, Mueckl K, Rao R, Brooks P, Geiler V, Gross G, Al-Hosni M, Shenoy S. Awareness of cord blood collection and the impact on banking. Pediatr Blood Cancer. 2017;64(7). PMID:28111924 
27. Abraham A, Cluster A, Jacobsohn D, Delgado D, Hulbert ML, Kukadiya D, Murray L, Shenoy S. Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial. Biol Blood Marrow Transplant. 2017. PMID:28578010 
28. Shenoy S, Angelucci E, Arnold SD, Baker KS, Bhatia M, Bresters D, Dietz AC, De La Fuente J, Duncan C, Gaziev J, King AA, Pulsipher MA, Smith AR, Walters MC. Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017;23(4):552-561. PMID:28065838 
29. Dietz AC, Duncan CN, Alter BP, Bresters D, Cowan MJ, Notarangelo L, Rosenberg PS, Shenoy S, Skinner R, Walters MC, Wagner J, Baker KS, Pulsipher MA. The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late Effects of Children Undergoing Hematopoietic Cell Transplantation for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies. Biol Blood Marrow Transplant. 2017;23(1):24-29. PMCID:PMC5267609  PMID:27737772 
30. Shenoy S, Eapen M, Panepinto JA, Logan BR, Wu J, Abraham A, Brochstein J, Chaudhury S, Godder K, Haight AE, Kasow KA, Leung K, Andreansky M, Bhatia M, Dalal J, Haines H, Jaroscak J, Lazarus HM, Levine JE, Krishnamurti L, Margolis D, Megason GC, Yu LC, Pulsipher MA, Gersten I, DiFronzo N, Horowitz MM, Walters MC, Kamani N. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood. 2016;128(21):2561-2567. PMCID:PMC5123194  PMID:27625358 
31. Madden LM, Hayashi RJ, Chan KW, Pulsipher MA, Douglas D, Hale GA, Chaudhury S, Haut P, Kasow KA, Gilman AL, Murray LM, Shenoy S. Long-Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Childhood Nonmalignant Disorders. Biol Blood Marrow Transplant. 2016;22(8):1467-72. PMID:27164064 
32. Madden LM, Hayashi RJ, Chan KW, Pulsipher MA, Douglas D, Hale GA, Chaudhury S, Haut P, Kasow KA, Gilman A, Murray LM, Shenoy S. Response to: "Technology and Long-Term Health-Related Quality-of-Life Outcomes in Children with Nonmalignant Disorders after Reduced-Intensity Conditioning and Stem Cell Transplantation". Biol Blood Marrow Transplant. 2016. PMID:27343717 
33. Shenoy S, Thompson AA. Unrelated donor stem cell transplantation for transfusion-dependent thalassemia. Ann N Y Acad Sci. 2016;1368(1):122-6. PMCID:PMC4870105  PMID:26999376 
34. King AA, Kamani N, Bunin N, Sahdev I, Brochstein J, Hayashi RJ, Grimley M, Abraham A, Dioguardi J, Chan KW, Douglas D, Adams R, Andreansky M, Anderson E, Gilman A, Chaudhury S, Yu L, Dalal J, Hale G, Cuvelier G, Jain A, Krajewski J, Gillio A, Kasow KA, Delgado D, Hanson E, Murray L, Shenoy S. Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. Am J Hematol. 2015. doi:10.1002/ajh.24183  PMID:26348869 
35. Ngwube A, Hayashi RJ, Murray L, Loechelt B, Dalal J, Jaroscak J, Shenoy S. Alemtuzumab based reduced intensity transplantation for pediatric severe aplastic anemia. Pediatr Blood Cancer. 2015;62(7):1270-6. doi:10.1002/pbc.25458  PMID:25755151 
36. Kothari A, Ngwube A, Hayashi R, Murray L, Davis J, Haut P, Loechelt BJ, Shenoy S. Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin. Biol Blood Marrow Transplant. 2015. doi:10.1016/j.bbmt.2015.03.019  PMID:25840334 
37. Madden LM, Ngwube AI, Shenoy S, Druley TE, Hayashi RJ. Late toxicity of a novel allogeneic stem cell transplant using single fraction total body irradiation for hematologic malignancies in children. J Pediatr Hematol Oncol. 2015;37(2):e94-e101. doi:10.1097/MPH.0000000000000272  PMCID:PMC4337424  PMID:25333837 
38. Shenoy S, Boelens JJ. Advances in unrelated and alternative donor hematopoietic cell transplantation for nonmalignant disorders. Curr Opin Pediatr. 2015;27(1):9-17. doi:10.1097/MOP.0000000000000179  PMCID:PMC4403859  PMID:25565572 
39. King A, Shenoy S. Evidence-based focused review of the status of hematopoietic stem cell transplantation as treatment of sickle cell disease and thalassemia. Blood. 2014;123(20):3089-94; quiz 3210. doi:10.1182/blood-2013-01-435776  PMID:24511087 
40. Bitan M, He W, Zhang MJ, Abdel-Azim H, Ayas MF, Bielorai B, Carpenter PA, Cairo MS, Diaz MA, Horan JT, Jodele S, Kitko CL, Schultz KR, Kletzel M, Kasow KA, Lehmann LE, Mehta PA, Shah N, Pulsipher MA, Prestidge T, Seber A, Shenoy S, Woolfrey AE, Yu LC, Davies SM. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood. 2014;123(10):1615-20. doi:10.1182/blood-2013-10-535716  PMCID:PMC3945869  PMID:24435046 
41. Uhlmann EJ, Shenoy S, Goodnough LT. Successful treatment of recurrent hyperhemolysis syndrome with immunosuppression and plasma-to-red blood cell exchange transfusion. Transfusion. 2014;54(2):384-8. doi:10.1111/trf.12258  PMID:23692505 
42. Shereck E, Shenoy S, Pulsipher M, Burns L, Bracey A, Chell J, Snyder E, Nemecek E. Exposure of early pediatric trainees to blood and marrow transplantation leads to higher recruitment to the field. Biol Blood Marrow Transplant. 2013;19(9):1399-402. doi:10.1016/j.bbmt.2013.06.021  PMID:23838095 
43. Schultz RK, Baker KS, Boelens JJ, Bollard CM, Egeler RM, Cowan M, Ladenstein R, Lankester A, Locatelli F, Lawitschka A, Levine JE, Loh M, Nemecek E, Niemeyer C, Prasad VK, Rocha V, Shenoy S, Strahm B, Veys P, Wall D, Bader P, Grupp SA, Pulsipher MA, Peters C. Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group. Biol Blood Marrow Transplant. 2013;19(9):1279-87. doi:10.1016/j.bbmt.2013.07.006  PMID:23883618 
44. Gadalla SM, Sales-Bonfim C, Carreras J, Alter BP, Antin JH, Ayas M, Bodhi P, Davis J, Davies SM, Deconinck E, Deeg HJ, Duerst RE, Fasth A, Ghavamzadeh A, Giri N, Goldman FD, Kolb EA, Krance R, Kurtzberg J, Leung WH, Srivastava A, Or R, Richman CM, Rosenberg PS, Toledo Codina JS, Shenoy S, Socié G, Tolar J, Williams KM, Eapen M, Savage SA. Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita. Biol Blood Marrow Transplant. 2013;19(8):1238-43. doi:10.1016/j.bbmt.2013.05.021  PMCID:PMC3736557  PMID:23751955 
45. Shenoy S. Umbilical cord blood: an evolving stem cell source for sickle cell disease transplants. Stem Cells Transl Med. 2013;2(5):337-40. doi:10.5966/sctm.2012-0180  PMCID:PMC3667562  PMID:23580541 
46. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher MA, Porter DL, Mineishi S, McCarty JM, Khan SP, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Bredeson C, Carter SL, Horowitz MM, Confer DL, Blood and Marrow Transplant Clinical Trials Network. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367(16):1487-96. doi:10.1056/NEJMoa1203517  PMID:23075175 
47. Siebrasse EA, Bauer I, Holtz LR, Le BM, Lassa-Claxton S, Canter C, Hmiel P, Shenoy S, Sweet S, Turmelle Y, Shepherd R, Wang D. Human polyomaviruses in children undergoing transplantation, United States, 2008-2010. Emerg Infect Dis. 2012;18(10):1676-9. doi:10.3201/eid1810.120359  PMCID:PMC3471627  PMID:23017293 
48. Kamani NR, Walters MC, Carter S, Aquino V, Brochstein JA, Chaudhury S, Eapen M, Freed BM, Grimley M, Levine JE, Logan B, Moore T, Panepinto J, Parikh S, Pulsipher MA, Sande J, Schultz KR, Spellman S, Shenoy S. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant. 2012;18(8):1265-72. doi:10.1016/j.bbmt.2012.01.019  PMCID:PMC3618440  PMID:22343376 
49. Patel VL, Mahévas M, Lee SY, Stasi R, Cunningham-Rundles S, Godeau B, Kanter J, Neufeld E, Taube T, Ramenghi U, Shenoy S, Ward MJ, Mihatov N, Patel VL, Bierling P, Lesser M, Cooper N, Bussel JB. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119(25):5989-95. doi:10.1182/blood-2011-11-393975  PMCID:PMC3383014  PMID:22566601 
50. Pranzatelli MR, Tate ED, Shenoy S, Travelstead AL. Ofatumumab for a rituximab-allergic child with chronic-relapsing paraneoplastic opsoclonus-myoclonus. Pediatr Blood Cancer. 2012;58(6):988-91. doi:10.1002/pbc.23187  PMID:21618414 
51. Shenoy S. Hematopoietic stem cell transplantation for sickle cell disease: current practice and emerging trends. Hematology Am Soc Hematol Educ Program. 2011;2011:273-9. doi:10.1182/asheducation-2011.1.273  PMID:22160045 
52. Pulsipher MA, Horwitz EM, Haight AE, Kadota R, Chen AR, Frangoul H, Cooper LJ, Jacobsohn DA, Goyal RK, Mitchell D, Nieder ML, Yanik G, Cowan MJ, Soni S, Gardner S, Shenoy S, Taylor D, Cairo M, Schultz KR. Advancement of pediatric blood and marrow transplantation research in North America: priorities of the Pediatric Blood and Marrow Transplant Consortium. Biol Blood Marrow Transplant. 2010;16(9):1212-21. doi:10.1016/j.bbmt.2009.12.536  PMCID:PMC2891395  PMID:20079865 
53. Buchanan G, Vichinsky E, Krishnamurti L, Shenoy S. Severe sickle cell disease--pathophysiology and therapy. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S64-7. doi:10.1016/j.bbmt.2009.10.001  PMCID:PMC2832723  PMID:19819341 
54. McDonald S, Wilson DB, Pumbo E, Kulkarni S, Mason PJ, Else T, Bessler M, Ferkol T, Shenoy S. Acquired monosomy 7 myelodysplastic syndrome in a child with clinical features suggestive of dyskeratosis congenita and IMAGe association. Pediatr Blood Cancer. 2010;54(1):154-7. doi:10.1002/pbc.22283  PMID:19760774 
55. Druley TE, Hayashi R, Mansur DB, Zhang QJ, Barnes Y, Trinkaus K, Witty S, Thomas T, Klein EE, DiPersio JF, Adkins D, Shenoy S. Early outcomes after allogeneic hematopoietic SCT in pediatric patients with hematologic malignancies following single fraction TBI. Bone Marrow Transplant. 2009;43(4):307-14. doi:10.1038/bmt.2008.327  PMCID:PMC2792985  PMID:19011666 
56. Bhatla D, Davies SM, Shenoy S, Harris RE, Crockett M, Shoultz L, Smolarek T, Bleesing J, Hansen M, Jodele S, Jordan M, Filipovich AH, Mehta PA. Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome. Bone Marrow Transplant. 2008;42(3):159-65. doi:10.1038/bmt.2008.151  PMID:18500373 
57. Rao A, Kelly M, Musselman M, Ramadas J, Wilson D, Grossman W, Shenoy S. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer. 2008;50(4):822-5. doi:10.1002/pbc.21264  PMID:17570702 
58. Hansen MD, Filipovich AH, Davies SM, Mehta P, Bleesing J, Jodele S, Hayashi R, Barnes Y, Shenoy S. Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen. Bone Marrow Transplant. 2008;41(4):349-53. doi:10.1038/sj.bmt.1705926  PMID:18026148 
59. Shenoy S. Stem cell transplantation in genetically linked regulatory T-cell disorders. Chem Immunol Allergy. 2008;94:211-9. doi:10.1159/000155089  PMID:18802350 
60. Shenoy S, Smith FO. Hematopoietic stem cell transplantation for childhood malignancies of myeloid origin. Bone Marrow Transplant. 2008;41(2):141-8. doi:10.1038/sj.bmt.1705961  PMID:18176616 
61. Shenoy S. Has stem cell transplantation come of age in the treatment of sickle cell disease? Bone Marrow Transplant. 2007;40(9):813-21. doi:10.1038/sj.bmt.1705779  PMID:17704797 
62. Fong T, Trinkaus K, Adkins D, Vij R, Devine SM, Tomasson M, Goodnough LT, Lopez S, Graubert T, Shenoy S, Dipersio JF, Khoury HJ. A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(10):1201-6. doi:10.1016/j.bbmt.2007.06.012  PMID:17889357 
63. Rao A, Kamani N, Filipovich A, Lee SM, Davies SM, Dalal J, Shenoy S. Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Blood. 2007;109(1):383-5. doi:10.1182/blood-2006-05-025072  PMID:16990602 
64. Oza A, Hallemeier C, Goodnough L, Khoury H, Shenoy S, Devine S, Augustin K, Vij R, Trinkaus K, Dipersio JF, Adkins D. Granulocyte-colony-stimulating factor-mobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor cell transplantation result in a modest reduction of febrile days and intravenous antibiotic usage. Transfusion. 2006;46(1):14-23. doi:10.1111/j.1537-2995.2005.00665.x  PMID:16398726 
65. Grewal SS, Wynn R, Abdenur JE, Burton BK, Gharib M, Haase C, Hayashi RJ, Shenoy S, Sillence D, Tiller GE, Dudek ME, van Royen-Kerkhof A, Wraith JE, Woodard P, Young GA, Wulffraat N, Whitley CB, Peters C. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med. 2005;7(2):143-6. doi:10.109701.GIM.0000154299.22120.6A  PMID:15714083 
66. Shenoy S, Grossman WJ, DiPersio J, Yu LC, Wilson D, Barnes YJ, Mohanakumar T, Rao A, Hayashi RJ. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant. 2005;35(4):345-52. doi:10.1038/sj.bmt.1704795  PMID:15592491 
67. Jeha S, Kantarjian H, Irwin D, Shen V, Shenoy S, Blaney S, Camitta B, Pui CH. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2005;19(1):34-8. doi:10.1038/sj.leu.2403566  PMID:15510203 
68. Khoury H, Trinkaus K, Zhang MJ, Adkins D, Brown R, Vij R, Goodnough LT, Ma MK, McLeod HL, Shenoy S, Horowitz M, Dipersio JF. Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. Biol Blood Marrow Transplant. 2003;9(11):714-21. doi:10.1016/j.bbmt.2003.08.006  PMID:14652855 
69. Vij R, DiPersio JF, Venkatraman P, Trinkaus K, Goodnough LT, Brown RA, Khoury HJ, Devine SM, Oza A, Shenoy S, Blum W, Adkins D. Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation. Blood. 2003;101(5):2067-9. doi:10.1182/blood-2002-07-2110  PMID:12406871 
70. Goral J, Shenoy S, Mohanakumar T, Clancy J Jr. Antibodies to 70 kD and 90 kD heat shock proteins are associated with graft-versus-host disease in peripheral blood stem cell transplant recipients. Clin Exp Immunol. 2002;127(3):553-9. PMCID:PMC1906313  PMID:11966775 
71. Shenoy S, Mohanakumar T, Chatila T, Tersak J, Duffy B, Wang R, Thilenius AR, Russell JH. Defective apoptosis in lymphocytes and the role of IL-2 in autoimmune hematologic cytopenias. Clin Immunol. 2001;99(2):266-75. doi:10.1006/clim.2001.5017  PMID:11318598 
72. Adkins DR, Goodnough LT, Shenoy S, Brown R, Moellering J, Khoury H, Vij R, DiPersio J. Effect of leukocyte compatibility on neutrophil increment after transfusion of granulocyte colony-stimulating factor-mobilized prophylactic granulocyte transfusions and on clinical outcomes after stem cell transplantation. Blood. 2000;95(11):3605-12. PMID:10828051 
73. Vij R, Brown R, Shenoy S, Haug JS, Kaesberg D, Adkins D, Goodnough LT, Khoury H, DiPersio J. Allogeneic peripheral blood stem cell transplantation following CD34+ enrichment by density gradient separation. Bone Marrow Transplant. 2000;25(12):1223-8. doi:10.1038/sj.bmt.1702427  PMID:10871725 
74. Shenoy S, Arnold S, Chatila T. Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome. J Pediatr. 2000;136(5):682-7. doi:10.1067/mpd.2000.105355  PMID:10802504 
75. Kraus MD, Shenoy S, Chatila T, Hess JL. Light microscopic, immunophenotypic, and molecular genetic study of autoimmune lymphoproliferative syndrome caused by fas mutation. Pediatr Dev Pathol. 2000;3(1):101-9. PMID:10594139 
76. Shenoy S, Mohanakumar T, Todd G, Westhoff W, Dunnigan K, Adkins DR, Brown RA, DiPersio JF. Immune reconstitution following allogeneic peripheral blood stem cell transplants. Bone Marrow Transplant. 1999;23(4):335-46. doi:10.1038/sj.bmt.1701581  PMID:10100577 
77. Sima T. Bhatt, Ginny Schulz, Monica Hente, Ashley Slater, Lisa Murray, Shalini Shenoy, Jeffrey J. Bednarski. A single‐center experience using alemtuzumab, fludarabine, melphalan, and thiotepa as conditioning for transplantation in pediatric patients with chronic granulomatous disease Pediatric Blood & Cancer 2019; ePub October 10.. PMID:31599480 
78. Ann Farrell, Julie Panepinto, Ankit Desai, Adetola Kassim, Jeffrey Lebensburger, Mark Walters, Daniel Bauer, Rae Blaylark, Donna DiMichele, Mark Gladwin, Nancy Green, Kathryn Hassell, Gregory Kato, Elizabeth Klings, Donald B Kohn, Lakshmanan Krishnamurti, Jane Little, Julie Makani, Punam Malik, Patrick McGann, Caterina Minniti, Claudia Morris, Isaac Odame, Patricia Oneal, Rosanna Setse, Poornima Sharma, and Shalini Shenoy. Endpoints for Sickle Cell Disease Clinical Trials: Renal and Cardiopulmonary, Cure, and Low-Resource Settings Blood Advances 2019. 
79. Shenoy S, Desch K, Duffy B, Thorson P, Mohanakumar T.. Analysis of graft-versus-host disease (GVHD) and graft rejection using MHC class I-deficient mice. Clin Exp Immunol 1998. 112(2):188-95. PMID:9649180 
80. Brown RA, Adkins D, Khoury H, Vij R, Goodnough LT, Shenoy S, DiPersio JF.. Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: graft-versus-host disease and transplant-related mortality. J Clin Oncol 1999. 17(3):806-12.. PMID:10071270 
81. Shenoy S. Hematopoietic stem-cell transplantation for sickle cell disease: current evidence and opinions. Ther Adv Hematol 2013. 4(5):335-44. PMID:24082994